{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:12:31Z","timestamp":1790878351390,"version":"4.1.0"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Structural Biology"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.sbi.2021.11.009","type":"journal-article","created":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T18:40:38Z","timestamp":1641494438000},"page":"267-278","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"special_numbering":"C","title":["Small molecule protein binding to correct cellular folding or stabilize the native state against misfolding and aggregation"],"prefix":"10.1016","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1330-1289","authenticated-orcid":false,"given":"Fabrizio","family":"Chiti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffery W.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.sbi.2021.11.009_bib1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1146\/annurev-biochem-061516-045115","article-title":"Protein misfolding, amyloid formation, and human disease: a summary of progress over the last decade","volume":"86","author":"Chiti","year":"2017","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.sbi.2021.11.009_bib2","doi-asserted-by":"crossref","first-page":"9629","DOI":"10.1073\/pnas.1121005109","article-title":"Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade","volume":"109","author":"Bulawa","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.sbi.2021.11.009_bib3","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1073\/pnas.68.6.1180","article-title":"Potassium cyanate as an inhibitor of the sickling of erythrocytes in\u00a0vitro","volume":"68","author":"Cerami","year":"1971","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.sbi.2021.11.009_bib4","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1073\/pnas.70.5.1313","article-title":"Acetylation of sickle cell hemoglobin by aspirin","volume":"70","author":"Klotz","year":"1973","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.sbi.2021.11.009_bib5","doi-asserted-by":"crossref","first-page":"8542","DOI":"10.1016\/S0021-9258(19)75254-5","article-title":"Schiff base adducts of hemoglobin. Modifications that inhibit erythrocyte sickling","volume":"252","author":"Zaugg","year":"1977","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.sbi.2021.11.009_bib6","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1476-5381.1984.tb10775.x","article-title":"Substituted benzaldehydes designed to increase the oxygen affinity of human haemoglobin and inhibit the sickling of sickle erythrocytes","volume":"82","author":"Beddell","year":"1984","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.sbi.2021.11.009_bib7","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1042\/cs0760357","article-title":"Pharmacological modification of oxygen affinity improves deformability of deoxygenated sickle erythrocytes: a possible therapeutic approach to sickle cell disease","volume":"76","author":"Keidan","year":"1989","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.sbi.2021.11.009_bib8","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1006\/bbrc.1995.2416","article-title":"Galactose stabilizes various missense mutants of alpha-galactosidase in Fabry disease","volume":"214","author":"Okumiya","year":"1995","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.sbi.2021.11.009_bib9","doi-asserted-by":"crossref","first-page":"15051","DOI":"10.1073\/pnas.93.26.15051","article-title":"Inhibiting transthyretin amyloid fibril formation via protein stabilization","volume":"93","author":"Miroy","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.sbi.2021.11.009_bib10","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1110\/ps.42401","article-title":"Reduction of the amyloidogenicity of a protein by specific binding of ligands to the native conformation","volume":"10","author":"Chiti","year":"2001","journal-title":"Protein Sci"},{"key":"10.1016\/j.sbi.2021.11.009_bib11","doi-asserted-by":"crossref","first-page":"6057","DOI":"10.1021\/jm0606488","article-title":"Stabilization of a native protein mediated by ligand binding inhibits amyloid formation independently of the aggregation pathway","volume":"49","author":"Soldi","year":"2006","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.sbi.2021.11.009_bib12","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1073\/pnas.0408277102","article-title":"Small-molecule-mediated stabilization of familial amyotrophic lateral sclerosis-linked superoxide dismutase mutants against unfolding and aggregation","volume":"102","author":"Ray","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.sbi.2021.11.009_bib13","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrd4593","article-title":"Targeting protein aggregation for the treatment of degenerative diseases","volume":"14","author":"Eisele","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.sbi.2021.11.009_bib14","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax0914","article-title":"Does protein aggregation drive postmitotic tissue degeneration?","volume":"13","author":"Kelly","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.sbi.2021.11.009_bib15","doi-asserted-by":"crossref","first-page":"107290","DOI":"10.1016\/j.compbiolchem.2020.107290","article-title":"A\u00a0database for structural and functional analysis on the impact of SNPs over transthyretin (TTR) using bioinformatic tools","volume":"87","author":"Srinivasan","year":"2020","journal-title":"Comput Biol Chem"},{"key":"10.1016\/j.sbi.2021.11.009_bib16","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.cell.2005.01.018","article-title":"The biological and chemical basis for tissue-selective amyloid disease","volume":"121","author":"Sekijima","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.sbi.2021.11.009_bib17","doi-asserted-by":"crossref","first-page":"16427","DOI":"10.1073\/pnas.202495199","article-title":"Sequence-dependent denaturation energetics: a major determinant in amyloid disease diversity","volume":"99","author":"Hammarstrom","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.sbi.2021.11.009_bib18","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1126\/science.1079589","article-title":"Prevention of transthyretin amyloid disease by changing protein misfolding energetics","volume":"299","author":"Hammarstrom","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.sbi.2021.11.009_bib19","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1002\/anie.200351179","article-title":"Benzoxazoles as transthyretin amyloid fibril inhibitors: synthesis, evaluation, and mechanism of action","volume":"42","author":"Razavi","year":"2003","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.sbi.2021.11.009_bib20","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1021\/jm0708735","article-title":"Biochemical and structural evaluation of highly selective 2-arylbenzoxazole-based transthyretin amyloidogenesis inhibitors","volume":"51","author":"Johnson","year":"2008","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.sbi.2021.11.009_bib21","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","article-title":"Tafamidis for transthyretin familial amyloid polyneuropathy A randomized, controlled trial","volume":"79","author":"Coelho","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.sbi.2021.11.009_bib22","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"ATTR-ACT study investigators: tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.sbi.2021.11.009_sref23","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1080\/13506129.2020.1808783","article-title":"Blinded potency comparison of transthyretin kinetic stabilisers by subunit exchange in human plasma","volume":"28","author":"Nelson","year":"2021","journal-title":"Amyloid"},{"key":"10.1016\/j.sbi.2021.11.009_bib24","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.tins.2020.10.002","article-title":"Microglial phagocytosis: a disease-associated process emerging from Alzheimer's disease genetics","volume":"43","author":"Podlesny-Drabiniok","year":"2020","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.sbi.2021.11.009_bib25","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/TP.0000000000000574","article-title":"Liver transplantation for hereditary transthyretin amyloidosis: after 20 Years still the best therapeutic alternative?","volume":"99","author":"Ericzon","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.sbi.2021.11.009_bib26","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.sbi.2021.11.009_bib27","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.sbi.2021.11.009_bib28","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in\u00a0vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.sbi.2021.11.009_bib29","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.sbi.2021.11.009_bib30","doi-asserted-by":"crossref","first-page":"6518","DOI":"10.3390\/ijms22126518","article-title":"Human \u03b1-galactosidase A mutants: priceless tools to develop novel therapies for Fabry disease","volume":"22","author":"Modrego","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.sbi.2021.11.009_bib31","doi-asserted-by":"crossref","first-page":"129437","DOI":"10.1016\/j.bbagen.2019.129437","article-title":"Progress in the understanding and treatment of Fabry disease","volume":"1864","author":"Miller","year":"2020","journal-title":"Biochim Biophys Acta Gen Subj"},{"key":"10.1016\/j.sbi.2021.11.009_bib32","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/4801","article-title":"Accelerated transport and maturation of lysosomal \u03b1\u2013galactosidase A in Fabry lymphoblasts by an enzyme inhibitor","volume":"5","author":"Fan","year":"1999","journal-title":"Nat Med"},{"key":"10.1016\/j.sbi.2021.11.009_bib33","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s40265-021-01486-1","article-title":"The current treatment landscape","volume":"81","author":"Lenders","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.sbi.2021.11.009_bib34","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.pcl.2016.04.002","article-title":"Molecular genetics of cystic fibrosis transmembrane conductance regulator: genotype and phenotype","volume":"63","author":"Sosnay","year":"2016","journal-title":"Pediatr Clin North Am"},{"key":"10.1016\/j.sbi.2021.11.009_bib35","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cell.2017.02.024","article-title":"Molecular structure of the human CFTR ion channel","volume":"169","author":"Liu","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.sbi.2021.11.009_bib36","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1126\/science.2475911","article-title":"Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA","volume":"245","author":"Riordan","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.sbi.2021.11.009_bib37","doi-asserted-by":"crossref","first-page":"FSO57","DOI":"10.4155\/fso.15.57","article-title":"Cystic fibrosis - a multiorgan protein misfolding disease","volume":"1","author":"Fraser-Pitt","year":"2015","journal-title":"Future Sci OA"},{"key":"10.1016\/j.sbi.2021.11.009_bib38","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.coph.2021.01.001","article-title":"Elexacaftor-tezacaftor-ivacaftor: the new paradigm to treat people with cystic fibrosis with at least one p.Phe508del mutation","volume":"57","author":"Gramegna","year":"2021","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.sbi.2021.11.009_bib39","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"VX08-770-102 Study Group. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.sbi.2021.11.009_bib40","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"TRAFFIC Study Group; TRANSPORT Study Group: lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.sbi.2021.11.009_bib41","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S2213-2600(16)30427-1","article-title":"Assess- ment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study","volume":"5","author":"Konstan","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.sbi.2021.11.009_bib42","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","article-title":"Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del","volume":"377","author":"Taylor-Cousar","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.sbi.2021.11.009_bib43","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1056\/NEJMoa1709847","article-title":"Tezacaftor-ivacaftor in residual-function heterozygotes with cystic fibrosis","volume":"377","author":"Rowe","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.sbi.2021.11.009_bib44","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1038\/s41591-018-0200-x","article-title":"Structure-guided combination therapy to potently improve the function of mutant CFTRs","volume":"24","author":"Veit","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.sbi.2021.11.009_bib45","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/prot.25496","article-title":"Comprehensive mapping of cystic fibrosis mutations to CFTR protein identifies mutation clusters and molecular docking predicts corrector binding site","volume":"86","author":"Molinski","year":"2018","journal-title":"Proteins"},{"key":"10.1016\/j.sbi.2021.11.009_sref46","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"VX17-445-102 Study Group: elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.sbi.2021.11.009_sref47","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"VX17-445-103 Trial Group: efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.sbi.2021.11.009_bib48","doi-asserted-by":"crossref","first-page":"2002774","DOI":"10.1183\/13993003.02774-2020","article-title":"Rescue of multiple class II CFTR mutations by elexacaftor+tezacaftor+ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator","volume":"57","author":"Laselva","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.sbi.2021.11.009_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2021.03.011","article-title":"Elexacaftor co-potentiates the activity of F508del and gating mutants of CFTR","author":"Veit","year":"2021","journal-title":"J\u00a0Cyst Fibros"},{"key":"10.1016\/j.sbi.2021.11.009_bib50","doi-asserted-by":"crossref","first-page":"4864","DOI":"10.1073\/pnas.71.12.4864","article-title":"Kinetics and mechanism of deoxyhemoglobin S gelation: a new approach to understanding sickle cell disease","volume":"71","author":"Hofrichter","year":"1974","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.sbi.2021.11.009_bib51","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/185416a0","article-title":"Structure of haemoglobin: a three-dimensional Fourier synthesis at 5.5-A. resolution, obtained by X-ray analysis","volume":"185","author":"Perutz","year":"1960","journal-title":"Nature"},{"key":"10.1016\/j.sbi.2021.11.009_bib52","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.1021\/jm0498001","article-title":"Structural basis for the potent antisickling effect of a novel class of five-membered heterocyclic aldehydic compounds","volume":"47","author":"Safo","year":"2004","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.sbi.2021.11.009_bib53","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1107\/S0907444911036353","article-title":"Crystallographic analysis of human hemoglobin elucidates the structural basis of the potent and dual antisickling activity of pyridyl derivatives of vanillin","volume":"67","author":"Abdulmalik","year":"2011","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1016\/j.sbi.2021.11.009_bib54","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/bjh.14214","article-title":"GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease","volume":"175","author":"Oksenberg","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.sbi.2021.11.009_sref55","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa1903212","article-title":"HOPE trial investigators: a phase 3 randomized trial of voxelotor in sickle cell disease","volume":"381","author":"Vichinsky","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.sbi.2021.11.009_bib56","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.3390\/biom10111508","article-title":"An investigation of structure-activity relationships of azolylacryloyl derivatives yielded potent and long-acting hemoglobin modulators for reversing erythrocyte sickling","volume":"10","author":"Omar","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.sbi.2021.11.009_bib57","doi-asserted-by":"crossref","first-page":"H400","DOI":"10.1152\/ajpheart.00048.2021","article-title":"Increased hemoglobin affinity for oxygen with gbt1118 improves hypoxia tolerance in sickle cell mice","volume":"321","author":"Dufu","year":"2021","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.sbi.2021.11.009_bib58","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.10935","article-title":"Inhibition by small-molecule ligands of formation of amyloid fibrils of an immunoglobulin light chain variable domain","volume":"4","author":"Brumshtein","year":"2015","journal-title":"Elife"},{"key":"10.1016\/j.sbi.2021.11.009_bib59","doi-asserted-by":"crossref","first-page":"8360","DOI":"10.1073\/pnas.1817567116","article-title":"Stabilization of amyloidogenic immunoglobulin light chains by small molecules","volume":"116","author":"Morgan","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.sbi.2021.11.009_sref60","doi-asserted-by":"crossref","first-page":"6273","DOI":"10.1021\/acs.jmedchem.1c00339","article-title":"Discovery of potent coumarin-based kinetic stabilizers of amyloidogenic immunoglobulin light chains using structure-based design","volume":"64","author":"Yan","year":"2021","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.sbi.2021.11.009_bib61","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.21037\/atm-20-1960","article-title":"Advances in pharmacotherapy of cataracts","volume":"8","author":"Xu","year":"2020","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.sbi.2021.11.009_bib62","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1126\/science.aac9145","article-title":"Pharmacological chaperone for alpha-crystallin partially restores transparency in cataract models","volume":"350","author":"Makley","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.sbi.2021.11.009_bib63","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nature14650","article-title":"Lanosterol reverses protein aggregation in cataracts","volume":"523","author":"Zhao","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.sbi.2021.11.009_sref64","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1167\/iovs.18-25647","article-title":"Mechanism of action of VP1-001 in cryAB(R120G)-associated and age-related cataracts","volume":"60","author":"Molnar","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.sbi.2021.11.009_bib65","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/nature01870","article-title":"A\u00a0camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme","volume":"424","author":"Dumoulin","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.sbi.2021.11.009_bib66","doi-asserted-by":"crossref","first-page":"937e944","DOI":"10.1021\/ja407527p","article-title":"Probing the N-terminal beta-sheet conversion in the crystal structure of the human prion protein bound to a nanobody","volume":"136","author":"Abskharon","year":"2014","journal-title":"J\u00a0Am Chem Soc"},{"key":"10.1016\/j.sbi.2021.11.009_bib67","doi-asserted-by":"crossref","first-page":"46711","DOI":"10.1038\/srep46711","article-title":"A\u00a0specific nanobody prevents amyloidogenesis of D76N \u03b22-microglobulin in\u00a0vitro and modifies its tissue distribution in\u00a0vivo","volume":"7","author":"Raimondi","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.sbi.2021.11.009_sref68","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.bbadis.2019.01.010","article-title":"Nanobody interaction unveils structure, dynamics and proteotoxicity of the Finnish-type amyloidogenic gelsolin variant","volume":"1865","author":"Giorgino","year":"2019","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10.1016\/j.sbi.2021.11.009_bib69","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/s41589-020-0555-4","article-title":"Discovery of small-molecule enzyme activators by activity-based protein profiling","volume":"16","author":"Kok","year":"2020","journal-title":"Nat Chem Biol"}],"container-title":["Current Opinion in Structural Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959440X21001585?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959440X21001585?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T13:27:03Z","timestamp":1760707623000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959440X21001585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":69,"alternative-id":["S0959440X21001585"],"URL":"https:\/\/doi.org\/10.1016\/j.sbi.2021.11.009","relation":{},"ISSN":["0959-440X"],"issn-type":[{"value":"0959-440X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Small molecule protein binding to correct cellular folding or stabilize the native state against misfolding and aggregation","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Structural Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.sbi.2021.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}